Suven Life Sciences Limited (SUVEN.BO)
INR 121.7
(2.4%)
INR 121.7
(2.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.63 Billion INR | -361.03% |
| 2022 | -354.13 Million INR | -1614.96% |
| 2021 | -20.65 Million INR | 54.96% |
| 2020 | -45.84 Million INR | 47.08% |
| 2019 | -86.63 Million INR | -447.65% |
| 2018 | 24.91 Million INR | -69.01% |
| 2017 | 80.41 Million INR | -87.05% |
| 2016 | 620.95 Million INR | 139.3% |
| 2015 | -1.57 Billion INR | 8.82% |
| 2014 | -1.73 Billion INR | -9826.52% |
| 2013 | -17.45 Million INR | -102.49% |
| 2012 | 701.76 Million INR | -6.07% |
| 2011 | 747.09 Million INR | 113.83% |
| 2010 | 349.39 Million INR | -26.95% |
| 2009 | 478.31 Million INR | 14.22% |
| 2008 | 418.77 Million INR | -18.81% |
| 2007 | 515.78 Million INR | 62.63% |
| 2006 | 317.15 Million INR | 42.18% |
| 2005 | 223.06 Million INR | 29.44% |
| 2004 | 172.32 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -71.92 Million INR | 0.0% |
| 2024 Q1 | - INR | 100.0% |
| 2023 FY | -1.63 Billion INR | -361.03% |
| 2023 Q3 | 1.97 Billion INR | 1235.92% |
| 2023 Q1 | 2.28 Billion INR | 745.03% |
| 2023 Q4 | -1.63 Billion INR | -182.55% |
| 2023 Q2 | -174.12 Million INR | -107.62% |
| 2022 Q2 | 351.75 Million INR | -30.26% |
| 2022 Q1 | 504.35 Million INR | 2542.4% |
| 2022 FY | -354.13 Million INR | -1614.96% |
| 2022 Q4 | -354.13 Million INR | -156.96% |
| 2022 Q3 | 621.78 Million INR | 76.76% |
| 2021 Q2 | -71.37 Million INR | -115.4% |
| 2021 Q3 | 211.23 Million INR | 395.95% |
| 2021 Q1 | 463.53 Million INR | 1111.08% |
| 2021 FY | -20.65 Million INR | 54.96% |
| 2021 Q4 | -20.65 Million INR | -109.78% |
| 2020 Q3 | 71.51 Million INR | 156.68% |
| 2020 Q1 | 151.41 Million INR | 274.78% |
| 2020 FY | -45.84 Million INR | 47.08% |
| 2020 Q2 | 27.86 Million INR | -81.6% |
| 2020 Q4 | -45.84 Million INR | -164.11% |
| 2019 Q3 | 1.53 Billion INR | 134.36% |
| 2019 FY | -86.63 Million INR | -447.65% |
| 2019 Q1 | 2.42 Billion INR | 9651.43% |
| 2019 Q2 | 656.71 Million INR | -72.97% |
| 2019 Q4 | -86.63 Million INR | -105.63% |
| 2018 FY | 24.91 Million INR | -69.01% |
| 2018 Q1 | 3.06 Billion INR | 0.0% |
| 2018 Q4 | 24.91 Million INR | 0.0% |
| 2017 FY | 80.41 Million INR | -87.05% |
| 2016 FY | 620.95 Million INR | 139.3% |
| 2016 Q4 | 620.95 Million INR | 0.0% |
| 2015 Q1 | 2.79 Billion INR | 261.43% |
| 2015 FY | -1.57 Billion INR | 8.82% |
| 2015 Q4 | -1.57 Billion INR | -163.18% |
| 2015 Q3 | 2.5 Billion INR | 209.18% |
| 2015 Q2 | 808.79 Million INR | -71.09% |
| 2014 Q4 | -1.73 Billion INR | -324.6% |
| 2014 Q2 | 438.53 Million INR | -36.84% |
| 2014 FY | -1.73 Billion INR | -9826.52% |
| 2014 Q1 | 694.36 Million INR | 4077.77% |
| 2014 Q3 | 771.5 Million INR | 75.93% |
| 2013 FY | -17.45 Million INR | -102.49% |
| 2013 Q4 | -17.45 Million INR | -106.96% |
| 2013 Q3 | 250.72 Million INR | -63.41% |
| 2013 Q2 | 685.2 Million INR | 213.48% |
| 2013 Q1 | 218.58 Million INR | -68.85% |
| 2012 Q2 | 1.4 Billion INR | 0.0% |
| 2012 Q4 | 701.76 Million INR | 0.0% |
| 2012 FY | 701.76 Million INR | -6.07% |
| 2011 FY | 747.09 Million INR | 113.83% |
| 2010 FY | 349.39 Million INR | -26.95% |
| 2009 FY | 478.31 Million INR | 14.22% |
| 2008 FY | 418.77 Million INR | -18.81% |
| 2007 FY | 515.78 Million INR | 62.63% |
| 2006 FY | 317.15 Million INR | 42.18% |
| 2005 FY | 223.06 Million INR | 29.44% |
| 2004 FY | 172.32 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 142.233% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 144.207% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 42.564% |
| Granules India Limited | 9.28 Billion INR | 117.581% |
| Indoco Remedies Limited | 6.47 Billion INR | 125.21% |
| Achyut Healthcare Limited | -3.74 Million INR | -43485.104% |
| Ajanta Pharma Limited | -954.9 Million INR | -70.981% |
| Alkem Laboratories Limited | -1.6 Billion INR | -1.448% |
| Alpa Laboratories Limited | 35.36 Million INR | 4716.967% |
| Brooks Laboratories Limited | 49.48 Million INR | 3399.38% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 67.427% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 149.491% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -41.023% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 112.644% |
| Eris Lifesciences Limited | 13.8 Billion INR | 111.826% |
| FDC Limited | -57.75 Million INR | -2727.085% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 61.9% |
| Gufic Biosciences Limited | 3.19 Billion INR | 151.113% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 60.687% |
| Ipca Laboratories Limited | 11.41 Billion INR | 114.303% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -17.466% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 184.468% |
| Lasa Supergenerics Limited | 205.79 Million INR | 893.346% |
| Laurus Labs Limited | 24.38 Billion INR | 106.696% |
| Lupin Limited | 17.19 Billion INR | 109.497% |
| Mankind Pharma Limited | -9.9 Billion INR | 83.521% |
| Medicamen Biotech Limited | 160.31 Million INR | 1118.425% |
| Medico Remedies Limited | 78.67 Million INR | 2175.191% |
| Megasoft Limited | 1.28 Billion INR | 227.004% |
| NATCO Pharma Limited | -5.81 Billion INR | 71.932% |
| Piramal Pharma Limited | 42.27 Billion INR | 103.862% |
| RPG Life Sciences Limited | -364.7 Million INR | -347.682% |
| Sigachi Industries Limited | 859.94 Million INR | 289.86% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 97.747% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 1226.185% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 3633.137% |
| Unichem Laboratories Limited | 931.91 Million INR | 275.198% |
| Wanbury Limited | 1.1 Billion INR | 247.639% |
| Windlas Biotech Limited | -273.04 Million INR | -497.97% |
| ZIM Laboratories Limited | 983.6 Million INR | 265.991% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 141.736% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -73.359% |
| Divi's Laboratories Limited | -39.77 Billion INR | 95.895% |
| Hester Biosciences Limited | 2.29 Billion INR | 171.274% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 30.464% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -556.25% |
| Bal Pharma Limited | 1.26 Billion INR | 229.214% |
| Strides Pharma Science Limited | 23.25 Billion INR | 107.02% |
| Venus Remedies Limited | -267.7 Million INR | -509.898% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 162.51% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 126.516% |
| Shilpa Medicare Limited | 9.06 Billion INR | 118.002% |
| Aarti Drugs Limited | 5.54 Billion INR | 129.426% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -48.252% |
| Ind-Swift Limited | 9.5 Billion INR | 117.171% |
| Valiant Laboratories Limited | -295.03 Million INR | -453.397% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 157.872% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 116.28% |
| Themis Medicare Limited | 764.96 Million INR | 313.435% |
| Hikal Limited | 7.96 Billion INR | 120.493% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 105.129% |
| Sequent Scientific Limited | 4.17 Billion INR | 139.073% |
| Novartis India Limited | -5.89 Billion INR | 72.285% |
| Wockhardt Limited | 18.27 Billion INR | 108.936% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 106.031% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -8751.231% |
| Neuland Laboratories Limited | -214.05 Million INR | -662.736% |
| Morepen Laboratories Limited | -231.17 Million INR | -606.264% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 1460.14% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 267.317% |